The Rapid Infectious Disease Testing market is forecast to grow at a CAGR of 6.9%, reaching USD 60.8 billion in 2031 from USD 43.6 billion in 2026.
The Rapid Infectious Disease Testing Market is experiencing substantial growth, driven by the imperative for rapid and accurate infection diagnostics. The immediate availability of results facilitates prompt therapeutic intervention and effective outbreak management. Increased prevalence of infectious diseases and the growing adoption of point-of-care (POC) testing are principal accelerators of market expansion.
Currently, diagnostics for rapidly disseminating pathogens encompass biological assays capable of swiftly identifying specific viruses within biological samples, such as blood or saliva. Technological advancements, particularly in diagnostic reagents, are enhancing laboratory efficiencies. This progress increases production capacities while simultaneously reducing the cost per unit tested. Rapid infectious disease tests are routinely employed for the diagnosis of diseases including influenza, SARS-CoV-2, HIV, and malaria. Their utility extends across diverse settings, from hospitals and ambulatory surgical centers to home-testing environments.
Increasing Prevalence of Infectious Diseases: The global increase in infectious disease prevalence (e.g., HIV, malaria, respiratory infections) drives substantial demand for rapid diagnostic tests and associated detection solutions.
Demand for Decentralized and Home-Based Testing: The convenience of point-of-care and home-based testing, significantly accelerated by the COVID-19 pandemic, has fueled demand for decentralized diagnostic solutions over traditional laboratory methods.
Government and Global Health Initiatives: Government organizations and global health initiatives, such as the World Health Organization (WHO), actively advocate for rapid diagnostics. This promotion emphasizes their critical role in early detection and outbreak control, particularly within low-resource and developing nations.
Technological Advancements in Diagnostic Platforms: Advancements in diagnostic platforms, encompassing biosensors, microfluidic technology, and molecular diagnostics, are enhancing test accuracy, speed, and usability. This progress facilitates broader adoption and integration of rapid diagnostic solutions.
The market contends with challenges including variable test accuracy, complexities in regulatory approvals, and infrastructure limitations in low-resource environments. Nevertheless, significant opportunities exist to propel sustained market growth. These include the expansion of at-home testing, the increasing integration of artificial intelligence (AI) in diagnostics, and the development of multiplex rapid tests. A sustained emphasis on early detection and enhanced global health preparedness will further underpin the market's long-term growth trajectory.
June 2025: bioMérieux enhanced its antimicrobial resistance (AMR) diagnostics portfolio through the acquisition of assets from Day Zero Diagnostics, a specialist in genome sequencing and machine learning-based infectious disease detection. This strategic acquisition is poised to expedite pathogen and antibiotic resistance profiling directly from blood samples, reducing diagnostic turnaround from days to hours.
The market is segmented by product type, technology, application, and geography.
Rapid test kits are widely deployed across hospitals, clinics, and home-use settings for the diagnosis of infectious diseases, including influenza, HIV, and malaria. Their expedited results render them highly valuable for point-of-care (POC) applications and large-scale screening initiatives. Consequently, the escalating demand for decentralized healthcare and early disease detection continues to fuel the adoption of rapid test kits for infectious disease diagnostics. Further enhancements in their sensitivity, specificity, and usability are expected to augment their efficacy in practical diagnostic scenarios.
In terms of technology, lateral flow assays are prevalent in rapid infectious disease testing due to their simplicity, cost-effectiveness, and rapid result delivery. These assays operate by identifying pathogens or antibodies within biological samples (e.g., blood, saliva, nasal swabs). Applications range from pregnancy tests and COVID-19 antigen tests to various rapid screening assays. Their inherent ease of use and minimal training requirements facilitate widespread adoption in point-of-care and home-based testing environments. Ongoing advancements in lateral flow assays are anticipated to improve accuracy and expand the spectrum of infectious diseases detectable by this technology.
Respiratory infections represent a dominant application segment, driven by high global prevalence and rapid transmission potential. Rapid diagnostic tests are extensively utilized for identifying infections including influenza, COVID-19, and respiratory syncytial virus (RSV). Prompt and precise detection is paramount for effective treatment and disease containment. Their deployment is widespread across hospitals, clinics, and public health screening initiatives. The heightened emphasis on outbreak preparedness and comprehensive respiratory disease management is fueling robust demand for rapid testing solutions within this segment.
North America's established healthcare system, substantial adoption of rapid diagnostic testing, and high incidence of infectious diseases establishes the region as the foremost market for diagnostic tests. The rising incidence of drug-resistant infections, coupled with the presence of leading industry players, underpins North America's dominant revenue share.
South America is progressively adopting advanced diagnostic solutions, commensurate with ongoing improvements in healthcare infrastructure. The increasing prevalence of infectious diseases is anticipated to escalate demand for antimicrobial resistance (AMR) diagnostics across South America. The region's countries are poised for consistent growth, driven by enhanced healthcare access and increasing awareness of rapid diagnostic testing benefits.
Europe's growth trajectory is sustained by heightened public awareness of antimicrobial resistance and robust regulatory frameworks. The region demonstrates consistent growth, underpinned by a resilient healthcare system, continuous expansion in rapid diagnostic test utilization, and governmental support for disease surveillance.
The Middle East and Africa (MEA) region exhibits nascent adoption of wearable biosensors, driven by improved healthcare accessibility and a growing interest in portable diagnostic technologies. Concurrently, the rising incidence of infectious diseases positions MEA as a growth market for point-of-care diagnostic technology adoption.
Asia Pacific is undergoing substantial growth, propelled by a high incidence of infectious diseases, a vast population base, and increasing healthcare expenditures. Asia Pacific records the highest growth rate, attributable to high population density, escalating infection rates, and enhanced investment in healthcare systems and diagnostics. Heightened governmental and public awareness of antimicrobial resistance (AMR), alongside governmental initiatives, further supports the adoption of AMR diagnostics in the region.
· Abbott Laboratories
· Roche Diagnostics
· Thermo Fisher Scientific
· Danaher Corporation
· bioMérieux
· BD (Becton, Dickinson and Company)
· QuidelOrtho Corporation
· Hologic
· SD Biosensor
· Access Bio
Abbott holds a leading position in the wearable biosensor market, notably within continuous glucose monitoring (CGM). Its FreeStyle Libre system has established an industry benchmark, enabling diabetic patients to monitor glucose levels continuously without traditional finger-prick methods. Abbott is integrating biosensors with mobile platforms to provide patients with real-time, continuous health status insights. Abbott's extensive global presence, unwavering commitment to innovation, and strategic development of digital health ecosystems through partnerships have solidified its leadership in wearable diagnostics.
bioMérieux is a premier provider of diagnostic solutions for infectious diseases and antimicrobial resistance (AMR) testing. Its integrated portfolio of automated systems, test reagents, and software empowers hospitals and laboratories to achieve rapid microorganism identification. This delivers crucial diagnostic data for initiating optimal and effective treatment strategies for patients with infectious diseases. Furthermore, bioMérieux prioritizes the development of innovative technologies and techniques to advance accurate and expedited infection detection through both microbiological and molecular diagnostic methodologies. With its expansive global footprint and profound expertise in infectious diseases, bioMérieux is uniquely positioned to drive advancements in AMR diagnostic products and services, thereby enhancing global healthcare delivery.
| Report Metric | Details |
|---|---|
| Total Market Size in 2026 | USD 43.6 billion |
| Total Market Size in 2031 | USD 60.8 billion |
| Forecast Unit | Billion |
| Growth Rate | 6.9% |
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Segmentation | Product Type, Technology, Application, Geography |
| Geographical Segmentation | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Companies |
|